Navigation Links
Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines
Date:1/24/2011

MANHATTAN BEACH, Calif., Jan. 24, 2011/PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced the company's support of the FDA's newly drafted "Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination." This guidance document, designed to encourage companies to collaborate and seek approval for successfully developed drug combinations, would support Genesis Biopharma's development of its anti-CD55 monoclonal antibody shown to have potentially broad application as a targeted cancer therapy.  

In particular, this guidance would help enable the company's goal to form partnerships with pharmaceutical and biotechnology companies and to support clinical development efforts for their anti-CD55 monoclonal antibody.

"Genesis Biopharma's anti-CD55 program has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development," said Robert Brooke, Genesis Biopharma President and CEO. "When this FDA guidance is finalized and approved, it will simplify efforts to form codevelopment partnerships and will ultimately ensure timely access to new and effective treatments for patients fighting currently sub-optimally treated conditions, such as metastatic cancer."  

"The regulatory professionals now have a much needed tool to guide companies when developing combinations of two investigational products toward the much needed goal of making available safe and effective therapies," added Dr. Hana B. Moran of Moran Advisors, LLC.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Raises $845,000 in Private Financings
2. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. Genesis Biopharma Announces $700K Private Financing
4. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
5. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
6. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
7. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
8. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
9. Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference
10. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
11. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
(Date:5/25/2016)... ... 2016 , ... Thailand’s Board of Investment’s New York office, ... Located at booth number 7301, representatives from the Thai Government, research organizations, and ... biotechnology and life sciences sector. , Deputy Secretary General of the Thailand ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Scientists at ... line options being tried for mesothelioma may be hampering the research that could lead ... research. Click here to read it now. , The team evaluated 98 ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell ... injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded ... healing and tissue regeneration. , The novel method, developed by WPI faculty members ...
Breaking Biology Technology:
(Date:3/15/2016)... New York , March 15, 2016 ... new market report published by Transparency Market Research "Digital Door ... Trends and Forecast 2015 - 2023," the global digital door ... US$ 731.9 Mn in 2014 and is forecast to grow ... 2023. Growth of micro, small and medium enterprises (MSMEs) across ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
Breaking Biology News(10 mins):